Tu canal independiente de oncología en español
Regístrate aquí para recibir más contenidos
Registrarse
OncoBites te trae los resúmenes y
presentaciones más relevantes del congreso
ESMO BREAST
2026
Top resúmenes y presentaciones
Addition of tucatinib to trastuzumab emtansine (T-DM1) in
patients with previously treated HER2+ locally
advanced/metastatic breast cancer (LA/MBC): updated
efficacy analysis from the HER2CLIMB-02 trial
423RO
Residual cancer burden (RCB) following neoadjuvant
treatment (NAT) with trastuzumab deruxtecan (T-DXd)
followed by paclitaxel + trastuzumab + pertuzumab
(THP) vs dose-dense doxorubicin + cyclophosphamide
followed by THP (ddAC-THP) in high-risk HER2+
early-stage breast cancer (eBC)
LBA1
Efficacy and safety of sacituzumab govitecan (SG) plus
trastuzumab in patients with HER2+ metastatic breast
cancer after prior trastuzumab deruxtecan (T-DXd): Results
from the phase II SATEEN trial
LBA4
Neoadjuvant trastuzumab, pertuzumab and tucatinib
without chemotherapy in HER2+ early breast cancer: the
TRAIN-4 study
217RO
ESMO BREAST 2026
HER2+
Tu canal independiente de oncología en español
Top resúmenes y presentaciones
Regístrate aquí para recibir más contenidos
Registrarse
ESMO BREAST 2026
TRIPLE NEGATIVO
Tu canal independiente de oncología en español
Top resúmenes y presentaciones
Regístrate aquí para recibir más contenidos
Registrarse
A comparative analysis between tissue-free ctDNA
detection and a multivariant tumour-informed assay in
early triple negative breast cancer
4RO
Pumitamig in combination with DB-1305/BNT325 as
first-line (1L) treatment for patients with advanced or
metastatic triple-negative breast cancer (a/mTNBC):
efficacy and safety from a multicenter, open-label, phase
1/2 trial
426RO
Randomized, Phase II Trial to Evaluate the Efficacy and
Safety of Atezolizumab plus Capecitabine Adjuvant Therapy
Compared to Capecitabine for Triple -Negative Breast
Cancer (TNBC) with Residual Invasive Cancer after
Neoadjuvant Chemotherapy (MIRINAE trial, KCSG-BR18-21)
215O
First-line (1L) datopotamab deruxtecan (Dato-DXd) vs
chemotherapy (CT) in patients (pts) with locally recurrent
inoperable or metastatic triple-negative breast cancer
(mTNBC) for whom immunotherapy was not an option:
Patient-reported outcomes (PROs) from
TROPION-Breast02
415O
A chemoresistance transcriptional signature identifies
high-risk triple-negative breast cancer (TNBC) beyond
pathologic complete response (pCR)
22P
Pretreatment TILs and pCR after neoadjuvant CT-ICI in
early-stage TNBC: a meta analysis
127eP
Efficacy of dose-dense platinum-based neoadjuvant
chemotherapy in triple negative breast cancer: real-world
outcomes in the overall population and a KEYNOTE-522 like
cohort
248P
ESMO BREAST 2026
TRIPLE NEGATIVO
Tu canal independiente de oncología en español
Top resúmenes y presentaciones
Regístrate aquí para recibir más contenidos
Registrarse
ESMO BREAST 2026
LUMINAL
Tu canal independiente de oncología en español
Top resúmenes y presentaciones
Regístrate aquí para recibir más contenidos
Registrarse
Efficacy of inavolisib (INAVO) + palbociclib (PALBO) +
fulvestrant (FULV) in patients (pts) with PIK3CA-mutated,
hormone receptor-positive, HER2-negative (HER2-),
endocrine-resistant advanced breast cancer (aBC) with and
without hyperglycaemia (HG) in the Phase III INAVO120 trial
420RO
Emergence of ESR1 mutations (ESR1m) in ctDNA during
first-line (1L) endocrine-based therapy in HR+/HER2_
advanced breast cancer: Findings from the SERENA-6
trial
419RO
Capivasertib (C) and fulvestrant (F) for patients (pts) with
HR+/HER2_ advanced breast cancer (ABC): final overall
survival (OS) results from the Phase 3 CAPItello-291 trial
417O
A window-of-opportunity (WOO) trial of giredestrant +/-
LHRH analogue vs anastrozole + LHRHa in
premenopausal patients with ER+/HER2- early breast
cancer: PREcoopERA
LBA2
ctDNA detection rates during surveillance in high-risk
HR+/HER2 negative breast cancer from the TRAK-ER study
1O